Gujarat Pharma Toxic Syrup Case

In early 2025, toxic cough syrups manufactured by Gujarat Pharmaceutical Company in India triggered an international health emergency. Pediatric syrup batches were found to be contaminated with diethylene glycol and ethylene glycol—industrial solvents used as cheap substitutes for pharmaceutical-grade propylene glycol. Dozens of children in India and multiple African nations suffered acute kidney injury, with at least 70 confirmed deaths. The Indian Central Drugs Standard Control Organization and the Gujarat Food and Drug Control Administration launched a joint investigation, uncovering that the company had falsified procurement records and bypassed safety testing. The World Health Organization issued a global medical product alert, urging nations to recall the syrups. The managing director and chief chemist were arrested, and the manufacturing license was cancelled. The case exposed critical gaps in India's drug regulation, including inadequate inspection of excipient suppliers. It also led to diplomatic tensions with affected countries demanding accountability and compensation. The trial commenced in a special court in Gujarat, focusing on charges of culpable homicide and criminal conspiracy.

As of 2025, the company’s license has been permanently revoked, several executives including the managing director are in custody, and the criminal trial is ongoing. No final verdict has been reached.

The primary disputes included whether the company intentionally used industrial-grade solvents to cut costs, the extent of liability of the directors versus lower-level employees, and the failure of Indian drug regulators to detect contamination during inspections. There were also contentious debates over jurisdiction and compensation for foreign victims.

The case triggered a worldwide loss of trust in Indian pharmaceutical products, leading to stricter regulatory oversight and the introduction of mandatory batch testing for exported syrups. It sparked diplomatic disputes between India and affected nations and energized civil society demands for corporate accountability in the pharma sector.